More on VRCA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+100.0% Growth)
- Ratings (5.6 Score)
- FDA

Upcoming Events

- Earnings (2/27/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Verrica Pharmaceuticals Inc. (NQ:VRCA)
Delayed: 5.31 +0.11 (2.12%)
Prev. Close $5.20  
Open$5.10 
52 Wk High$ 
52 Wk Low$ 
Day High$5.35 
Day Low$5.09 
P/E N/A  
EPS$ 
Volume71,434 

Friends, Peers and Foes (?): ESPR TVTX (more...)

Mar 5, 2026 08:00 AM Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
Feb 23, 2026 08:00 AM Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Feb 17, 2026 09:39 PM Form SCHEDULE 13G/A Verrica Pharmaceuticals Filed by: ARMISTICE CAPITAL, LLC
Feb 12, 2026 08:00 AM Verrica Pharmaceuticals names Chris Chapman chief commercial officer
Feb 12, 2026 08:00 AM Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
Feb 9, 2026 08:03 AM Verrica partner launches YCANTH molluscum treatment in Japan
Feb 9, 2026 08:00 AM Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
Feb 2, 2026 09:09 AM Form 3/A Verrica Pharmaceuticals For: Nov 25 Filed by: BKB Growth Investments, LLC
Jan 29, 2026 07:59 PM Form SCHEDULE 13G/A Verrica Pharmaceuticals Filed by: Affinity Asset Advisors, LLC
Jan 26, 2026 04:24 PM Form 3 Verrica Pharmaceuticals For: Nov 25 Filed by: BKB Growth Investments, LLC
View All Articles

Entities mentioned with VRCA

View All Entities